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Aim: The ﬁrst aim of this study was to determine levels of clusterin in pediatric patients
with systemic inﬂammatory response syndrome or septic state, comparing these levels
with a healthy population. The second objective was to compare levels of clusterin within
individual septic conditions, inﬂuence of levels of these proteins on mortality. Background:
Clusterin is a highly conserved protein which is expressed at increased levels by many cell
types in response to a broad variety of stress conditions. Methods: Fifty-seven children
aged 0–19 years (30 boys and 27 girls) hospitalized from June 2009 to March 2011, with
expected or proven SIRS and septic condition. The degree of severity was evaluated accor-
ding PELOD Score. Blood tests to determine levels of clusterin were taken throughout the
patient meets the criteria of SIRS or sepsis. Control group to determine the serum levels of
clusterin has been taken from patients undergoing elective surgery. Results: We found
lower concentrations of clusterin in patients with SIRS or septic state, than in the control
group. Clusterin cut-off for ﬁrst day – D1 was 91.04 mg/ml; AUC 0.900; p-value <0.001; for
third day – D3 was cut-off 86.73 mg/ml; AUC 0.849; p-value <0.001; for ﬁfth day – D5 cut-off
was 105.26 mg/ml; AUC 0.755; p-value <0.001. Effect of clusterin levels on mortality in the
dynamics was recorded signiﬁcant for 5 days in groups non-survivors/survivors, p-value
0.004. Conclusion: We have demonstrated a decrease clusterin levels in pediatric patients
with septic state, and its effect on mortality.
© 2012 Polish Pediatric Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.Introduction
Sepsis is the most common cause of death in infants and
children in the world [1]. The incidence of pediatric sepsis
has been recently estimated to be 0.56/1000 children with
the highest incidence in infancy at 5.6/1000; overall morta-
lity is 10.6% [2]. Sepsis is a complex, highly variable,
multiple system, clinical process induced by pathogens that* Corresponding author at: Černopolní 9, Brno, 62500, Czech Republic.
E-mail address: jzurek@fnbrno.cz (Ž. Jiří).
0031-3939/$ – see front matter © 2012 Polish Pediatric Society. Publish
http://dx.doi.org/10.1016/j.pepo.2012.11.004causes a deleterious, systemic host response [3]. Organ
dysfunction is the ﬁnal tissue sequelae in response to severe
sepsis and the ultimate determinant of survival. It has been
amply demonstrated that septic hosts who have progressive
multiple organ failure are much more likely to succumb to
severe sepsis than those who develop a single or no organ
dysfunction in response to sepsis [4, 5].
The diagnosis of sepsis and evaluation of its severity is
complicated by the highly variable and non-speciﬁc natureTel.: +420 53223 4695; fax: +420 53223 4252.
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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diagnosis and stratiﬁcation of the severity of sepsis is very
important, increasing the possibility of starting timely and
speciﬁc treatment [7]. Biomarkers can have an important
place in this process since they can indicate the presence/
absence or severity of sepsis [8]. One of the potential
biomarkers with the chaperone-like activity is clusterin.
Clusterin
The clusterin protein was ﬁrst discovered more than 25 years
ago in rat testis ﬂuid because of its ability to facilitate
clustering of a variety of cell types in culture [9]. It is a
75–80-kDa disulﬁde-linked heterodimeric protein with about
30% of the mass of the molecule comprised of N-linked
carbohydrate which is branched, complex, and rich in sialic
acid [10].
Clusterin is an enigmatic molecule, implicated in diverse
biological processes, and has additionally been associated
with opposing functions in regard to apoptosis [11]. Possible
protective mechanisms are considered by blockage of the
terminal complement cascade (C5b-9) or by protecting
against oxidative stress [12, 13]. More recent studies show
that clusterin may be a secreted chaperone molecule,
inhibiting stress-induced precipitation of a very broad range
of structurally divergent protein substrates and binding
irreversibly via an ATP-independent mechanism to stressed
proteins to form solubilized high molecular weight comple-
xes [14, 15].
The ﬁrst aim of this study was to determine levels of
clusterin in pediatric patients with systemic inﬂammatory
response syndrome (SIRS) or septic state, comparing these
levels with a healthy population. The second objective was
to compare levels of clusterin within individual septic
conditions, and inﬂuence of levels of this protein on
mortality.Fig. 1 – Distribution of clusterin levels in individual septic
states. SIRS – systemic inflammatory response syndrome;
MODS – multiple organ dysfunction syndromeMaterials and methods
Prospective observational study occurred during the period
from June 2009 to March 2011. The study protocol and
informed consent approach were approved by the Ethics
committee of the University Hospital, Brno. Parents provided
informed written consent for their children to participate in
this trial. Data were collected and analyzed from ﬁfty-seven
consecutive patients with SIRS or septic state who were
admitted to the Department of Anesthesia and Intensive
Care of the University Children's Hospital Brno, Czech
Republic. The most common sources of infection that led to
sepsis were the lungs – bacterial and viral infections, and
central nervous system – bacterial infections of the brain.
Infections, sepsis, severe sepsis, septic shock and multiple
organ dysfunction syndrome (MODS) were deﬁned according
to commonly used criteria – by International pediatric sepsis
consensus conference. The criteria for adult SIRS were
modiﬁed for pediatric use. Age-speciﬁc norms of vital signs
and laboratory data were incorporated into the deﬁnitions
of SIRS. Sepsis was deﬁned as SIRS associated with suspec-
ted or proven infection [16]. Patients were categorized intoﬁve groups according to their clinical data and to the
described deﬁnitions: (a) SIRS, (b) sepsis, (c) severe sepsis, (d)
septic shock, (e) MODS. In these groups, we compared the
difference in the levels of clusterin. The samples from 70
children undergoing elective surgery were used as controls
(strabismus surgery, umbilical and inguinal hernia repair),
i.e. samples from patients without signs of infection. Blood
samples were collected before surgery.
Patient data were recorded at the time of diagnosis of
SIRS or sepsis, severe sepsis, septic shock and multiple
organ dysfunction syndrome and consisted of age, sex,
Pediatric Logistic Organ Dysfunction (PELOD), length of
hospitalization [17]. PELOD score is a tool which is used to
characterize severity of organ dysfunction in critically ill
child. Score which is given to each organ will increase
according the severity of organ dysfunction so PELOD score
can be used to predict severity of organ dysfunction.
The PELOD scoring system consists of physical and labora-
tory variables representing 6 organs, namely nervous, car-
diovascular, renal, respiratory, hematologic, and hepatic
system [17]. Value of PELOD 12 was taken as the average of
the whole set.
Specimens for the diagnosis of infection were obtained
as early as possible.
Complete medical history and clinical examination, labo-
ratory parameters, and disease-speciﬁc examinations were
evaluated.
Blood samples were obtained from a central venous
catheter during the ﬁrst 12 h after the diagnosis SIRS or
septic state, or at the beginning of surgery in the control
group. For the evaluation of clusterin dynamics, samples
were collected at all times when patients meet the criteria
SIRS or septic state.
Samples were allowed to clot at room temperature and
were centrifuged at 3000 rpm for 10 min. Separated serum
was stored at 80 8C until further analysis. Samples were
[(Fig._1)TD$FIG]
Table I – Descriptive characteristics of patients, data are presented as median (min–max)
N </, Age (month) LOS PICU PELOD score
Survivors 51 28/23 8 (1–219) 7.5 (1–19) 11 (1–22)
Non-survivors 6 2/4 90.5 (3–186) 7.0 (1–41) 26 (11–41)
LOS PICU – length of stay in the pediatric intensive care unit, PELOD score – pediatric logistic organ dysfunction.
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measurement (BioVendor, Laboratorní medicína a.s., Brno,
Czech Republic). Samples were incubated in microplate
wells pre-coated with monoclonal anti-human clusterin
antibody. After 60 min incubation and washing, biotin
labeled second monoclonal anti-human clusterin antibody
was added and incubated with captured clusterin for
60 min. After another washing, streptavidin-HRP conjugate
was added. After 30 min incubation and the last washing
step, the remaining conjugate was allowed to react with the
substrate solution (TMB). The reaction was stopped by
addition of acidic solution and absorbance of the resulting
yellow product was measured. The absorbance is proportio-
nal to the concentration of clusterin.[(Fig._2)TD$FIG]
Fig. 2 – Clusterin levels (mg/ml) in the control group and in the g
syndrome or sepsis, severe sepsis, septic shock or multiple orga
curve; SE – sensitivity; SP – specifity; PV+ – positive predictive vThe laboratory technicians performing the assays were
completely blinded to the clinical information.
Statistical analysis
Baseline levels of analyzed protein and demographic cha-
racteristics were summarized using descriptive statistics
(N, mean, standard deviation, median, minimum, maximum).
The analysis was performed on logarithmically transformed
data to achieve an approximately normal distribution of the
evaluated data. The dynamics (kinetics) of the protein levels
during the period of SIRS or septic state were analyzed using
the analysis of variance (ANOVA). Correlation of values in
the patients was performed using a symmetric covarianceroup of patients with systemic inflammatory response
n dysfunction syndrome during a 5-days. AUC – area under
alue; PVS – negative predictive value
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difference in dynamics between analyzed groups is indicated
by p-value of group and time interaction effect. ROC analysis
was performed to determine the discriminatory characteris-
tics of the protein values. ROC curves are shown together
with the respective diagnostic characteristics (sensitivity,
speciﬁcity, positive and negative predictive values).Results
The study included ﬁfty-seven children patients, whose
characteristics are presented in Table I.
Lowered values of clusterin suggest altered clinical con-
dition (systemic inﬂammation or sepsis). Lowest values can
be observed in the most severe clinical condition; SIRS ﬁrst
day D1 – median (min–max) 3.8 (1.1–274.0), sepsis D1 –
median (min–max) 97.8 (3.5–335.0), severe sepsis D1 median
(min–max) 65.3 (5.8–216.0), septic shock D1 median (min–
max) 45.8 (1.8–371.0) (Fig. 1).
Clusterin levels in the control group were compared with
a group of patients who were diagnosed with SIRS or sepsis,
severe sepsis, septic shock or MODS during a 5-days.
Generally, we found lower concentrations of clusterin in
patients with SIRS or septic state, than in the control group.
Clusterin cut-off for ﬁrst day – D1 was 91.04 mg/ml; AUC
[(Fig._3)TD$FIG]
Fig. 3 – Correlation dependence between clusterin levels (mg/ml)
syndrome; MODS – multiple organ dysfunction syndrome; AUC
PV+ – positive predictive value; PVS – negative predictive value;
ROC – receiver operating characteristic0.900; p-value <0.001; for third day – D3 was cut-off
86.73 mg/ml; AUC 0.849; p-value <0.001; for ﬁfth day – D5
cut-off was 105.26 mg/ml; AUC 0.755; p-value <0.001 (Fig. 2).
During the evaluation of correlation dependence between
clusterin levels and septic state, patients were divided into
two groups – SIRS and sepsis vs. severe sepsis + septic
shock + multiple organ dysfunction syndrome (MODS). Hig-
her values were considered to be associated with worse
septic condition (as resulted from ROC optimal discrimina-
tion, however weak and non-signiﬁcant). The difference in
the dynamics of clusterin levels was recorded signiﬁcant for
5 days in these groups, p-value 0.031 (Fig. 3).
When the patients were divided into two subgroups
(PELOD score <12 and PELOD score >12), the evaluation of
clusterin levels according to the degree of severity state
showed that that there is no statistically signiﬁcant diffe-
rence between the these two groups. The difference in the
dynamics of clusterin levels for 5 days was recorded, p-value
0.031. In group of patients with PELOD > 12 there is
a signiﬁcant increase of clusterin levels in third days of
hospitalization, thus in patients with more severe condition
(Fig. 4). Analysis of the control group versus PELOD score
>12 showed a signiﬁcant statistical difference, the cut-off
91.04 mg/ml, AUC 0.939, p-value <0.001 (Fig. 5).
We also assessed the effect of clusterin levels on morta-
lity in patients. There is no statistically signiﬁcant differenceand septic states. SIRS – systemic inflammatory response
– area under curve; SE – sensitivity; SP – specifity;
ANOVA – analysis of variance; G. mean – geometric mean;
[(Fig._4)TD$FIG]
Fig. 4 – The evaluation of clusterin levels (mg/ml) and Pediatric Logistic Organ Dysfunction Score. PELOD Score – pediatric
logistic organ dysfunction; AUC – area under curve; SE – sensitivity; SP – specifity; PV+ – positive predictive value; PVS –
negative predictive value; ANOVA – analysis of variance; G. mean – geometric mean; ROC – receiver operating characteristic[(Fig._5)TD$FIG]
Fig. 5 – Analysis of the patients in control group versus Pediatric Logistic Organ Dysfunction Score. PELOD Score – pediatric
logistic organ dysfunction; AUC – area under curve; SE – sensitivity; SP – specifity; PV+ – positive predictive value;
PVS – negative predictive value
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Fig. 6 – The values of clusterin (mg/ml) for the first five days of hospitalization in patients who died and who survived.
AUC – area under curve; SE – sensitivity; SP – specifity; PV+ – positive predictive value; PVS – negative predictive value;
ANOVA – analysis of variance; G. mean – geometric mean
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even though they were very borderline signiﬁcance. The
difference in the dynamics of clusterin levels was recorded
signiﬁcant for 5 days in these groups, p-value 0.004. Thus in
patients who died clusterin levels increase was very slow
over time (Fig. 6).Discussion
In sepsis, the expected and appropriate inﬂammatory res-
ponse to an infectious process becomes ampliﬁed leading to
organ dysfunction or risk for secondary infection.
A continuum exists from a low grade systemic response
associated with a self-limited infection to a marked syste-
mic response with solitary or multiorgan dysfunction, i.e.,
severe sepsis. As a clinical syndrome, sepsis occurs when
an infection is associated with the systemic inﬂammatory
response [18].
Many cellular aspects become dysfunctional in sepsis and
may be characterized as either excessive activation or depres-
sed function. One of the current areas of active investigation
concerning cellular function is the induction of cellular
apoptosis or necrosis. The signaling mechanisms and mole-
cules that induce apoptosis are currently being described in
great detail by a number of investigators [19, 20].Clusterin is widely distributed, well conserved, and
constitutively secreted glykoprotein that is highly induced
in tissues regressing as a consequence of apoptotic cell
death. Clusterin gene expression decreases drastically in
cells undergoing apoptotic cell death in vitro, but continues
to be expressed by morphologically normal cells [21].
In the hypothesis that clusterin may be have as a stress
protein we have analyzed its expression in response to SIRS
or septic state. This report demonstrates that clusterin
expression is down-regulated in response to the above
states. We demonstrated lower concentrations of clusterin
in patients with SIRS or septic state, than in the control
group. We did not ﬁnd the difference in levels of clusterin
between the different states. When evaluating the levels of
clusterin and PELOD score, we experienced statistical signi-
ﬁcance in the dynamics of protein. This we consider very
important, because a decrease or increase of the protein
indicates the severity of the patient status. We have also
demonstrated mortality prediction based on dynamics of
clusterin levels.Unfortunately, we can not compare our
results with others, because data from the pediatric popula-
tion and from septic patients are not available.In adult
patients with sepsis and septic shock clusterin was highly
up-regulated in survivors, with expression factors of 26.5
and 14.9, whereas non-survivors exhibited only up-regula-
tion levels of 3.1 and 5.9 [22]. In acute meningococcal
p e d i a t r i a p o l s k a 8 8 ( 2 0 1 3 ) 6 – 1 312disease, clusterin concentrations were lower in sepsis
patients than in non-sepsis patients. In non-survivors,
a modest increase was seen in patients after admission and
this was followed by a further decline before death. In
survivors, a considerable increase was seen from day 2 to
day 6 but no difference was seen between admission and
day 2 or between day 6 and week 6. The values found at day
6 and week 6 were comparable to values previously deter-
mined in serum samples from healthy blood donors [23].
In the experimental animal study a signiﬁcant reduction
in pulmonary hypertension and edema has been demon-
strated due to a protective effect of clusterin in granulocyte
induced pulmonary injury [24]. Clusterin expression is also
upregulated in rats following traumatic brain injury [25], in
seizure [26] and in some neurodegenerative diseases, such
as Parkinson's disease and Alzheimer's disease [27, 28]. The
role of clusterin in brain cell death is contradictory, as both
gene-deﬁciency and overexpression of clusterin inhibic brain
damage in mice [29].
Although biomarkers of sepsis are not widely used in
research or clinical practice, it is possible to evaluate the
utility of approaches that are currently available. The
optimal use of biomarkers as surrogates in informing
the design of deﬁnitive clinical trials presupposes a valid
and extensive understanding of the natural history of the
biomarker in the population of interest, and how its levels
are modiﬁed by therapeutic intervention [8]. These data
can then be integrated using meta-analytic techniques to
evaluate the capacity of a biomarker to predict a clinically
important outcome [30]. A methodology for evaluating the
level of evidence that a given biomarker might serve as
a reliable surrogate outcome measure has recently been
proposed, but its utility in the assessment of biomarkers
for diseases such as sepsis where mortality is conside-
rable is unknown [31].
In conclusion, we here provide the ﬁrst clusterin serum
analysis of pediatric patients with sepsis and septic shock.
We have shown a signiﬁcant relationship between the levels
of clusterin and pediatric patients with septic state. Further
studies are required to elucidate the clinical impact of the
observed organ-protective properties of clusterin and next
studies are needed to examine his potential roles as
predictive outcome markers, as well as his precise functio-
nal roles in sepsis, or possible therapeutic potential.Authors' contributions/Wkład autorów
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